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• Coronary Artery Stenosis Morphology and Degree 
of Vasomotion in Patients With Prinzmetars 
Variant Angina 
Dimitris Tousoulis, Graham Davies, Agha W. Halder, Juan Cados KaskL 
Cardiology Units, RPMS and St" George's Hospital Medical School, London 
UK 
In patients with chronic stable angina eccentric stenoses have a larger 
potential for dynamic changes of calibre than concentric stonoses. Whether 
the same occurs in patients with variant angina is not known. We compared 
vasomotor eactivity of eccentric (asymmetric narrowings) and concentric 
(symmetric narrowings) stanases in 22 patients (17 male, 5 female, mean 
age 49 ± 8 years) with Prinzmetal's angina and in 20 patients (18 male, 2 
female, mean age 53 :t: 12 years) with chronic Stable angina. The responses 
to intracorona~y ergonovine and isosorbide dinitrate were studied at both 
spastic and non spastic q i~  using computerized quantitative angiegraphy, 
Diameters of eccentric and concentric stonosas were measuredbefore and 
after the administration ofboth ergonovine and nitrate. In patients with variant 
angina, argonovine (20 p.g) triggered focal coronary spasm in all patients; 
it caused total corenary occlusion in 3 of 13 (23%) eccentric and in 3 of 
10 (30%) concentric stenoses (p = NS). Mean stanosis diameter eduction 
with ergonovine was 59.0 ± 7,0% and 66 ± 10% in eccentdc and concentdc 
stenoses, respectively (p = NS). Isosorbide dinitrate (1-2 rag) promptly 
relieved spasm in all patients and increased mean did, meter of eccentric and 
concentric stenoses from 1,46 ± 0.10 (baseline prior to spasm) to 1,73 ± 
0.16 mm (17,6 ± 6% change) and from 1.63 ± 0,16 to 1.88 ± 0,23 mm (13 ± 
6% change) (p = NS). In patients with chronic stable angina ergonovine (20 
p.g) reduced stanosis diameter (by > 10%) in 80% of eccentric stonosss and 
46% of concentric stanoses (p < 0.01). Mean (± SEM) diameter eduction 
with erganovine was -18.7 ± 2.7 and -9,9 ± 2.4=/0, for eccentric and 
concentric stanases respectively (p < 0.05). Isosorbide dinitrate increased 
coronary diameter (by > 10%) in 70% of eccentric and 38% of concentric 
stenoses (p < 0.01). Mean diameter dilation with nitrate was 15,1 ± 3.0 
and 9.6 ± 3.8% for eccentric and concentric stanoses respectively (p = 
NS). In conclusion the results of this study indicate that in patients with 
variant angina: 1) a similar proportion of eccentric and concentric stenoses 
react in response to vasoactive stimuli, and 2) the magnitude of changes 
in caliber was similar in eccentric and concentric stanoses. However in 
patients with stable angina a signiticent proportion of eccentric that concentric 
stenoses react in response to ergonovine and nitrate. Thus the hyperraactive 
coronary segments of patients with Prinzmetal's angina can change their 
caliber significantly, irrespective of the angiographic morphology. 
~ Platelet Activation in Unstable Angina Is Inhibited 
by r-Hlrudin, but Not by Heparin 
Zihui Xian, Pierre Th~roux. Montreal Heart Institute, Montreal, Quebec, 
Canada 
Platelet function was characterized by flow cytometry in whole blood in 7 pa- 
tients with unstable angina before and 4 to 12 hours after administration fiv 
r-hirudin (r-HIr, 0.15 mg/kg/min) and hepadn (Hep, 1000 U/hr). Fluorescein- 
labeled antibodies were used to quantify platelet activation, PAC-1 for acti- 
vated GP IIb/Uta and CD62 for P-salectin, in the basal state and following 
egonlal stimulation with adenosine diphosphate (ADP), 0.31 p.M, and with 
PAC-1 CD62 
% PI BI % PI BI 
Pre-Hir basal 4.0~3,2 5.4±1.4 
ADP 78.4±12.9 5.5±3.2 21.5±7.6 
TRAP 25.7=1:19,8 0.9±0.8 21.0±20 
r.Hir basal 1.44-1.5* 4.3±1,9 
ADP 64.04-18.5" 3.8±2.91" 1&3±&3* 
TRAP 4.7:1:5.7' 0.5:t:1 15.34-16.2' 
Pre.Hap basal ~.6:~1.9 6,2±4.5 
AOP 62,6±15,4 3.4:k.2,2 17.4±12.9 
TRAP 9.7±7.4 0 ,34-0 .3  11.2±7.7 
Hsp basal 1.9:t:1.5 5,5±3,4 
ADP 68.44-15.2 4 .04-2.8  14.7±8,1 
TRAP 8,2:1:11.1 0,3±0.4 12.9±10.6 
=p < 0.05; "tp < 0.01, VS Pre-H[r 
0.44-0.2 
0,45+0.6 
0.25~:0.2" 
0.34-0.4 
0.3±0.2 
0,24-0.1 
0.2:t:0.1 
0.2±0.2 
a thrombin receptor agonist peptide (TRAP), 0.625 p.M. The percentage of 
fluorescein positive platelets (% PI) and the binding index per platalet (BI) 
were calculated. The aPTT was prolonged similarly to two times control with 
the two drugs, r-hirudin, but not Hep, reduced activation of GP lib/Ilia and 
P-salectin expression, see table. 
The results show more adequate control of platelet activity in unstable 
angina with r-hirudin compared to heparin, suggesting more profound inhibi- 
tion of thrembin activity with the direct thrombin inhibitor. 
~ ' 7  The Protective Effect of Lmw in Unstable Heparin 
Coronary Artery Oisease Is Related to the 
Fibrlnogen Level 
Henrik Toss, Agneta Siegbahn 1 Lars Wallentin. Dept. of Cardiology, 
University Hospital, Uppsala, Sweden; ~ Dept. of Clin. Chemistry, University 
Hospital, Uppsala, 6~eden 
In a multicentor, prospective, placebo controlled study evaluating the effect of 
daltaparin, a low molecular weight heparin 0mwh), 546 patients with unstable 
coronary artery disease, i,e. unstable angina and non-Q-wave AMI, with 
latest episode of chest-pain within 72 hours were included. ECG criteria to 
be fulfilled was transient or persisting ST-depression and/or T-weve inversion t 
Patients with indications for thrembolytic treatment were excluded. 
The patients were randomized to dalteparin 120 IU/kg s.c. twice daily 6 -  
8 days and thereafter self-administrating 7500 IU once daily the following 
35 days. If not contraindicated all patients were treated with aspirin and 
p-blockers. A subsequent AMI or death during the 150 days follow-up were 
considered as an end-point. At inclusion P-fibdnogen (Fib) was measured by 
nephelometry. 
Evaluation of event rates (%) was based on quartiles of tibrinogen levels. 
Fib. g/L Day 6 Day 40 Day 150 
Placebo LMWH Placebo LMWH Placebo LMWH 
< 3.2 3,0 0 9.0 1A 13.4 5.5 
3.2-3.5 5.5 1.6 9.7 3,2 12.5 14.3 
3,6-4.1 1.4 0 8,1 8.5 14.9 15,3 
> 4.1 4.8 3,9 14.5 13.2 22.6 25.5 
Conclusion: During treatment with 120 IU/kg event rates seemed reduced 
regardless of librinogan levels. In treatment with 7500 IU once dally the 
event rates decreased only in groups with tibdnogen levels below medium 
value. After termination of daltepadn the protective ffect remained only in 
the lowest quartile. 
~ Plasminogen Activator Inhibitor-1 Is a Determinant 
of Coronary Thrombosis in Sudden Cardiac Death 
Andrew Farb, Allen P. Burke, Frank D. Kdodgie, Poonam Mannan, 
You-hut Liang, John Smialek, Renu V;,,,anL Armed Forces Institute of 
Pathology, Washington, DC 
We assessed the expression of plasminogen activator inhibitor-1 (PAl-l) and 
tissue factor in human atherosolerotic cerenary artedes with and without 
acute thrombosis. Light microscopy and immunocytochemistry (using mono- 
ctonal antibodies directed against PAl-1 and tissue factor) were performed on 
34 atheresclemtic coronary arteries from individuals with sudden death (27 
males, 7 females; mean age 47 4- 10 years). Of these vessels, 24 had acute 
thrombosis: 12 had thrombi associated with plaque rupture (PR) invc:Mng di;- 
ruption of a fibrous cap over a lipid core, and 12 demonstrated acute thrombi 
ovedying a supedicial ulceration (SU) of proteoglycan and smooth muscle 
cell-rich plaque. There was local PAl-1 positive staining of macrophages and 
smooth muscle cells (SMC's) in 7 of 12 arteries with PR. In artadas with 
SU, 9 of 12 vessels demonstrated strong PAl-1 pasitivity in SMC's with focal 
staining in mscrophagas. PAl-1 staining in the 10 non4hrombosed coronary 
arteries (mean area stenosis 58 4- 23=/=) was negative xcept for two cases 
which showed only weak poaltivity. In total, 16 of 24 (670/-) thrombosed 
arteries demonstrated PAl-1 positivity, compared with only 2 of 10 (20"/0) 
vessels with stable plaques (p = 0.035). Immunoalalns for tissue factor in the 
same thmmbesed and non-thrombosed arteries demonstrated strong diffuse 
positivity in intimal SMC's and macrophages with weak staining of medial SM- 
O's. Conclusion: PAl-1 expression is enhanced in atherosclerotic cemnary 
arteries with acute ceranary thrombosis, whereas tissue factor expression 
is ubiquitous in thrombosed and non-thrombosed arteries. Increased PAl-1 
activity may precipitate thrombosis in cases of sudden cardiac death. 
